You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePancuronium
Accession NumberDB01337
TypeSmall Molecule
GroupsApproved
DescriptionA bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
Structure
Thumb
Synonyms
Bromure de pancuronium
Bromuro de pancuronio
Pancuronium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pancuronium Bromide - Liq IV 1mg/mlLiquid1 mgIntravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Pancuronium Bromide - Liq IV 2mg/mlLiquid2 mgIntravenousSandoz Canada Incorporated1996-12-31Not applicableCanada
Pancuronium Bromide 1mg/mlSolution1 mgIntravenousHospira Healthcare Corporation1996-10-24Not applicableCanada
Pancuronium Bromide 2mg/mlSolution2 mgIntravenousHospira Healthcare Corporation1995-12-31Not applicableCanada
Pavulon Inj 1mg/mlLiquid1 mgIntravenousOrganon Canada Ltd Ltee1979-12-311997-08-18Canada
Pavulon Inj 2mg/mlLiquid2 mgIntravenousOrganon Canada Ltd Ltee1973-12-311997-08-18Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pancuronium BromideInjection, solution1 mg/mLIntravenousHospira, Inc.1989-01-19Not applicableUs
Pancuronium BromideInjection, solution1 mg/mLIntravenousTeva Parenteral Medicines, Inc.1990-08-01Not applicableUs
Pancuronium BromideInjection, solution2 mg/mLIntravenousTeva Parenteral Medicines, Inc.1990-08-01Not applicableUs
Pancuronium BromideInjection, solution2 mg/mLIntravenousTeva Parenteral Medicines, Inc.1990-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MioblockNot Available
PavulonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pancuronium bromide
15500-66-0
Thumb
  • InChI Key: NPIJXCQZLFKBMV-YTGGZNJNSA-L
  • Monoisotopic Mass: 730.291983712
  • Average Mass: 732.67
DBSALT000368
Categories
UNIIJ76UF062FS
CAS numberNot Available
WeightAverage: 572.8619
Monoisotopic: 572.455308418
Chemical FormulaC35H60N2O4
InChI KeyGVEAYVLWDAFXET-XGHATYIMSA-N
InChI
InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
IUPAC Name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-13-(1-methylpiperidin-1-ium-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-4-yl]-1-methylpiperidin-1-ium
SMILES
[H][C@@]12C[C@@H]([[email protected]](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[[email protected]](OC(C)=O)[[email protected]](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1
Pharmacology
IndicationUsed as a muscle relaxant during anesthesia and surgical procedures.
Structured Indications Not Available
PharmacodynamicsPancuronium is a typical non-depolarising curare-mimetic muscle relaxant. It acts as a competitive acetylcholine antagonist on neuromuscular junctions, displacing acetylcholine (hence competitive) from its post-synaptic nicotinic acetylcholine receptors. It is, unlike suxamethonium, a non-depolarising agent, which means, that it causes no spontaneous depolarisations upon association with the nicotinic receptor in neuromuscular junction, thus producing no muscle fasciculations upon administration. Pancuronium has no hormonal activity. It exerts slight vagolytic activity (i.e. diminishing activity of the vagus nerve) and no ganglioplegic (i.e., blocking ganglions) activity.
Mechanism of actionNondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.
TargetKindPharmacological actionActionsOrganismUniProt ID
Neuronal acetylcholine receptor subunit alpha-2Proteinyes
antagonist
HumanQ15822 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 241 to 280 mL/kg
Protein binding77 to 91%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life1.5 to 2.7 hours.
Clearance
  • Plasma cl=1.1–1.9 mL/minute/kg
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AcetyldigitoxinPancuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AclarubicinAclarubicin may increase the respiratory depressant activities of Pancuronium.Investigational
AclidiniumAclidinium may increase the anticholinergic activities of Pancuronium.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Ambenonium.Approved
Ambroxol acefyllinateThe risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Pancuronium.Experimental
AmikacinAmikacin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
AminophyllineThe risk or severity of adverse effects can be increased when Aminophylline is combined with Pancuronium.Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pancuronium.Approved
annamycinannamycin may increase the respiratory depressant activities of Pancuronium.Investigational
AnvirzelPancuronium may increase the arrhythmogenic activities of Anvirzel.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Pancuronium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Pancuronium.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pancuronium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pancuronium.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pancuronium.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pancuronium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pancuronium.Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational
Botulinum Toxin Type BPancuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Pancuronium.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Butorphanol.Approved, Illicit, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Pancuronium.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Pancuronium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Pancuronium.Approved
CimetropiumPancuronium may increase the anticholinergic activities of Cimetropium.Experimental
ClindamycinClindamycin may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
CoumaphosThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pancuronium.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational, Vet Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pancuronium.Approved, Investigational
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Pancuronium.Approved
DecamethoniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Pancuronium.Approved
DeslanosidePancuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pancuronium.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pancuronium.Approved
DigitoxinPancuronium may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinPancuronium may increase the arrhythmogenic activities of Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Pancuronium.Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Pancuronium is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Donepezil.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pancuronium is combined with DPDPE.Investigational
DronabinolPancuronium may increase the tachycardic activities of Dronabinol.Approved, Illicit
DyphyllineThe risk or severity of adverse effects can be increased when Dyphylline is combined with Pancuronium.Approved
EchothiophateThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Edrophonium.Approved
EluxadolinePancuronium may increase the constipating activities of Eluxadoline.Approved
EpirubicinEpirubicin may increase the respiratory depressant activities of Pancuronium.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Pancuronium.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pancuronium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Etorphine.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fesoterodine.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Pancuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pancuronium.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Pancuronium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Pancuronium.Experimental
Ginkgo bilobaThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.Approved
GlycopyrroniumPancuronium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Pancuronium is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pancuronium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pancuronium.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Pancuronium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pancuronium.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Pancuronium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Pancuronium.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Pancuronium.Investigational
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.Approved
IsoflurophateThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pancuronium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pancuronium is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Levorphanol.Approved
LithiumLithium may increase the neuromuscular blocking activities of Pancuronium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Lofentanil.Illicit
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Pancuronium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Pancuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Pancuronium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
MalathionThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pancuronium.Approved
MefloquineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pancuronium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pancuronium.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Pancuronium.Approved
MetixeneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Pancuronium.Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Pancuronium.Approved
MianserinMianserin may increase the anticholinergic activities of Pancuronium.Approved
MinaprineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Pancuronium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Pancuronium is combined with N-butylscopolammonium bromide.Vet Approved
NabilonePancuronium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Pancuronium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Pancuronium.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Pancuronium is combined with NVA237.Investigational
OpiumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pancuronium.Approved
OuabainPancuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pancuronium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pancuronium.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pancuronium.Approved
PethidineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pethidine.Approved
PhysostigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pipecuronium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Pancuronium.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pancuronium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Pancuronium.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Piritramide.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Pancuronium.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Pancuronium.Approved
Potassium ChloridePancuronium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Pancuronium.Approved, Investigational
ProcainamideProcainamide may increase the neuromuscular blocking activities of Pancuronium.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pancuronium.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pancuronium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Propiverine.Investigational
PuromycinPuromycin may increase the respiratory depressant activities of Pancuronium.Experimental
PyridostigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Pancuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Pancuronium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Pancuronium.Approved
RamosetronPancuronium may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Pancuronium.Approved
RivastigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Pancuronium.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Pancuronium.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Pancuronium is combined with Solifenacin.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Pancuronium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Pancuronium.Approved
SufentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pancuronium.Approved
TacrineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tapentadol.Approved
TetracyclineTetracycline may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
TheophyllineThe risk or severity of adverse effects can be increased when Theophylline is combined with Pancuronium.Approved
TiotropiumPancuronium may increase the anticholinergic activities of Tiotropium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pancuronium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Pancuronium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Pancuronium.Approved
TramadolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Pancuronium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pancuronium.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pancuronium.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pancuronium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pancuronium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pancuronium.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Pancuronium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Pancuronium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Pancuronium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Vecuronium.Approved
ZorubicinZorubicin may increase the respiratory depressant activities of Pancuronium.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM03AC01
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8913
Blood Brain Barrier+0.878
Caco-2 permeable+0.5457
P-glycoprotein substrateSubstrate0.77
P-glycoprotein inhibitor IInhibitor0.6962
P-glycoprotein inhibitor IIInhibitor0.6508
Renal organic cation transporterNon-inhibitor0.6862
CYP450 2C9 substrateNon-substrate0.8382
CYP450 2D6 substrateNon-substrate0.7638
CYP450 3A4 substrateSubstrate0.742
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9229
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9368
Ames testNon AMES toxic0.7499
CarcinogenicityNon-carcinogens0.9265
BiodegradationNot ready biodegradable0.8557
Rat acute toxicity2.6653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9021
hERG inhibition (predictor II)Non-inhibitor0.7784
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous2 mg/mL
LiquidIntravenous1 mg
LiquidIntravenous2 mg
SolutionIntravenous1 mg
SolutionIntravenous2 mg
Prices
Unit descriptionCostUnit
Pancuronium 2 mg/ml vial2.59USD ml
Pancuronium 1 mg/ml vial0.13USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point215 °CPhysProp
water solubility5E+005 mg/LMERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility3.08e-06 mg/mLALOGPS
logP1.04ALOGPS
logP-3.3ChemAxon
logS-8.3ALOGPS
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity185.22 m3·mol-1ChemAxon
Polarizability69.44 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androstane-skeleton
  • Cyclohexylamine
  • Piperidine
  • Acetate salt
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Dilger JP, Vidal AM, Liu M, Mettewie C, Suzuki T, Pham A, Demazumder D: Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists. Anesthesiology. 2007 Jun;106(6):1186-95. [PubMed:17525594 ]
  3. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Milchert M, Spassov A, Meissner K, Nedeljkov V, Lehmann C, Wendt M, Loster BW, Mazurkiewicz-Janik M, Gedrange T, Pavlovic D: Skeletal muscle relaxants inhibit rat tracheal smooth muscle tone in vitro. J Physiol Pharmacol. 2009 Dec;60 Suppl 8:5-11. [PubMed:20400785 ]
  2. Cembala TM, Forde SC, Appadu BL, Lambert DG: Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors. Eur J Pharmacol. 2007 Aug 13;569(1-2):37-40. Epub 2007 May 22. [PubMed:17588565 ]
  3. Okanlami OA, Fryer AD, Hirshman C: Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61. [PubMed:8572329 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Milchert M, Spassov A, Meissner K, Nedeljkov V, Lehmann C, Wendt M, Loster BW, Mazurkiewicz-Janik M, Gedrange T, Pavlovic D: Skeletal muscle relaxants inhibit rat tracheal smooth muscle tone in vitro. J Physiol Pharmacol. 2009 Dec;60 Suppl 8:5-11. [PubMed:20400785 ]
  2. Okanlami OA, Fryer AD, Hirshman C: Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61. [PubMed:8572329 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Stovner J, Oftedal N, Holmboe J: The inhibition of cholinesterases by pancuronium. Br J Anaesth. 1975 Sep;47(9):949-54. [PubMed:1191483 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  2. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H: Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem. 1996 Dec 20;271(51):32599-604. [PubMed:8955087 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81. [PubMed:9260930 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:07 / Updated on August 17, 2016 12:23